In recent months, the regulatory landscape surrounding tirzepatide has shifted significantly, particularly after the FDA confirmed that the drug shortage affecting this medication has been resolved. This development comes as MEDVi, a telehealth platform based in Newark, DE, continues to expand its offerings of GLP-1 weight loss medications.
MEDVi has made a name for itself by providing access to compounded GLP-1 injections and tablets, with pricing starting at $179 for the first month of injections and $249 for oral tablets. Monthly refills for these compounded injections are priced at $299, while the branded Ozempic injection remains at a steep $1,999 per month.
Matthew Gallagher, the founder of MEDVi, has reported impressive growth, with the company achieving $401 million in sales in 2025 and projecting a remarkable $1.8 billion for 2026. Gallagher noted, “Growth was insane,” highlighting the rapid increase in customer base from 300 in the first month to 1,300 in the second month.
MEDVi’s innovative approach includes a conditional refund policy for weight loss after a commitment of five months, which has attracted many users seeking effective weight management solutions. As Gallagher explained, “The body takes time to acclimate to GLP-1 medication,” indicating the importance of patient education and support throughout the treatment process.
Furthermore, the evaluating clinician retains the decision to prescribe, ensuring that patients receive tailored care based on their individual health needs. This personalized approach is a cornerstone of MEDVi’s telehealth services.
With a net profit margin of 16.2% in 2025, generating approximately $65 million in profit, MEDVi’s business model is proving to be both sustainable and scalable. The company, operated by MEDVi, LLC, is located at 131 Continental Dr, Ste 305, Newark, DE 19713.
As the healthcare community watches these developments closely, observers are optimistic about MEDVi’s future and its potential to make a significant impact in the weight loss medication market. The resolution of the tirzepatide shortage is expected to further enhance MEDVi’s offerings and accessibility.
In summary, MEDVi’s innovative use of technology and strategic partnerships has positioned it as a leader in the telehealth space, and the recent changes in the regulatory environment are likely to bolster its growth trajectory.
